 PLANEGGMUNICH, GERMANY ACCESSWIRE November 2, 2021 MorphoSys AG FSE:MOR; NASDAQ:MOR today announces that revenues from product sales of Monjuvi R tafasitamab-cxix in the U.S. amount to 18.6 million US 22 million for the third quarter of 2021 and 46.4 million US 55.5 million for the first nine months of 2021. Monjuvi R is being co-commercialized by Incyte and MorphoSys in the United States. 